BRAF mutation analysis and sonography as adjuncts to fine-needle aspiration cytology of papillary thyroid carcinoma: Their relationships and roles

American Journal of Roentgenology

Volumn 198, Issue 3, 2012, Pages 668-674

  Moon, Won Jin ^a   Choi, Nami ^a   Choi, Jin Woo ^a   Kim, Suk Kyeong ^a   Hwang, Tae Sook ^a  

^a Konkuk University Hospital   (South Korea)

Author keywords

BRAF mutation; Fine needle biopsy; Papillary carcinoma; Protooncogene proteins; Sonography; Thyroid neoplasms

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; ASPIRATION CYTOLOGY; BRAF GENE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ECHOGRAPHY; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THYROID NODULE; THYROID PAPILLARY CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 84863237562     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.7185     Document Type: Article

References (39)

1. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002; 87:1941-1946 (Pubitemid 34521470)
2. Kim EK, Park CS, Chung WY, et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR 2002; 178:687-691
3. Moon WJ, Jung SL, Lee JH, et al. Benign and malignant thyroid nodules: US differentiation - multicenter retrospective study. Radiology 2008; 247:762-770
4. Gharib H, Goellner JR, Zinsmeister AR, Grant CS, Van Heerden JA. Fine-needle aspiration biopsy of the thyroid: the problem of suspicious cytologic findings. Ann Intern Med 1984; 101:25-28 (Pubitemid 14088062)
5. Alexander EK. Approach to the patient with a cytologically indeterminate thyroid nodule. J Clin Endocrinol Metab 2008; 93:4175-4182 (Pubitemid 352789508)
6. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12:245-262 (Pubitemid 40896444)
7. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28:742-762 (Pubitemid 350294294)
8. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004; 45:818-821 (Pubitemid 39545368)
9. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006; 65:364-368
10. 600E mutation-prevalent area. Clin Endocrinol (Oxf) 2006; 65:660-666
11. V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasonographic classification: a potential guide for selection of samples for molecular analysis. Thyroid 2010; 20:273-279
12. V600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 2009; 253:854-860
13. V600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 2008; 17:118-125
14. V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin Endocrinol (Oxf) 2009; 70:139-144
15. V600E mutation: sonographic prediction. AJR 2010; 194:1344; [web] W425-W430
16. Baloch ZW, Cibas ES, Clark DP, et al. The National Cancer Institute thyroid fine needle aspiration state of the science conference: a summation. Cytojournal 2008; 5:6
17. Koh CS, Ku JL, Park SY, et al. Establishment and characterization of cell lines from three human thyroid carcinomas: responses to all-trans-retinoic acid and mutations in the BRAF gene. Mol Cell Endocrinol 2007; 264:118-127
18. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002; 13:3-16 (Pubitemid 34665111)
19. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000; 289:1357-1360 [Erratum in Science 2000; 289:1474] (Pubitemid 30656054)
20. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954 (Pubitemid 34716871)
21. Costa AM, Herrero A, Fresno MF, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2008; 68:618-634 (Pubitemid 351388702)
22. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003; 1653:25-40 (Pubitemid 36627818)
23. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004; 5:875-885 (Pubitemid 39486539)
24. MacCorkle RA, Tan TH. Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys 2005; 43:451-461 (Pubitemid 41506881)
25. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997; 9:180-186 (Pubitemid 27135985)
26. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med 2006; 38:200-211 (Pubitemid 43675585)
27. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4:937-947 (Pubitemid 39626217)
28. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004; 6:313-319 (Pubitemid 39361432)
29. V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110:38-46
30. Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 2009; 56:89-97
31. Michels JJ, Jacques M, Henry-Amar M, Bardet S. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol 2007; 38:212-219 (Pubitemid 46096555)
32. V600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology. Ann Surg Oncol 2009; 16:3125-3131
33. Pizzolanti G, Russo L, Richiusa P, et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid 2007; 17:1109-1115 (Pubitemid 350207747)
34. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-1214 [Errata in Thyroid 2010; 20:674-675 and 2010; 20:942]
35. Moon WJ, Kwag HJ, Na DG. Are there any specific ultrasound findings of nodular hyperplasia ("leave me alone" lesion) to differentiate it from follicular adenoma? Acta Radiol 2009; 50:383-388
36. Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 2009; 94:1748-1751
37. V600E mutation status. J Clin Endocrinol Metab 2011; 96:658-664
38. Pazaitou-Panayiotou K, Capezzone M, Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinomas. Thyroid 2007; 17:1085-1092 (Pubitemid 350207746)
39. Moon WJ, Baek JH, Jung SL, et al.; Korean Society of Thyroid Radiology; Korean Society of Radiology. Ultrasonography and the ultrasoundbased management of thyroid nodules: consensus statement and recommendations. Korean J Radiol 2011; 12:1-14